The actor stars as Chris, the boyfriend of the unwitting groom-to-be in Andrew Ahn's remake of the Ang Lee classic The post ...

The remake will feature a number of changes including the addition of a lesbian couple at the centre of the plot The post BFI ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

The Gladstone Institutes is comprised of three institutes in the San Francisco area which began in 1979. The Gladstone Institute of Cardiovascular Disease focuses on atherosclerosis and its ...

If shaving is growing tiresome, consider laser hair removal: This method damages hair follicles to reduce growth over time, ultimately giving more long-term results than using a razor. After ...

Prince Harry has released a new official photo and the Duke of Sussex appears to have undergone quite the hair transformation for the new image. The new snap was released by BetterUp, an ...

If your regular shampoo and conditioner aren't quite giving you all the shine and frizz control you're looking for, you may need to call in a pinch hitter: a hair gloss. These innovative ...

OnlyFans stars Lilly Phillips and Bonnie Blue are vying to have sex with more men, a feud that drove social media crazy back in 2024, when Phillips met the challenge of sleeping with 100 men in 24 ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors. Lilly on Tuesday ...

Lilly plans to share its full Q4 2024 results on 6 February 2025. Credit: JHVEPhoto via Getty Images. Eli Lilly has announced a $400m reduction in its 2024 revenue forecast, marking a 3% shortfall ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 revenue guidance, which fell short of Wall Street expectations. The ...